PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 2026Frontiers of Nursing0 citationsOpen Access

Nursing management for ICANS of CAR T-cell therapy in B cell acute lymphoblastic leukemia †

HYHui-Yao YangJJJing-Jing JinQZQian-Qian Zhang

Key Points

  • Timely and accurate treatment improves the management of ICANS during CAR T-cell therapy, ensuring patient safety.
  • Developed nursing procedures include close monitoring of vital signs and personalized care plans tailored to individual needs.

Structured PICO

P
Population
Patients with B cell acute lymphoblastic leukemia receiving CAR T-cell therapy at risk for or experiencing Immune effector cell-associated neurotoxic syndrome (ICANS)
I
Intervention
Standardized nursing procedures and management for ICANS
O
Outcome
Development of nursing procedures for ICANS

Standardized nursing procedures for ICANS during CAR T-cell therapy provide a framework to improve patient safety and manage this life-threatening complication.

Abstract

Abstract Objective Immune effector cell-associated neurotoxic syndrome (ICANS) is one of the most concerning complications because of its life-threatening trait during chimeric antigen receptor (CAR) T-cell therapy and requires specialized management. We summarized the nursing procedures of CAR T-cell therapy for ICANS to provide some references for the standardized nursing care of ICANS. Methods Based on previous experience and literature research, the professional team developed nursing procedures for ICANS for patients receiving CAR T-cell therapy. Results The professional team developed step-by-step, sophisticated care procedures before, during, and after ICANS, including active communication and collaboration, knowledge updates, personalized nursing plans, advanced assessments, close monitoring of vital signs and laboratory tests, medication plans, timely and correct drug administration, dietary nursing interventions, safety care, nursing of other complications, follow-up of toxicities, and keeping an eye on the potential side effects. Conclusions ICANS is unique, with varying clinical symptoms and rapid progression. Timely and accurate treatment and care of patients is an effective way to manage ICANS. Professional and detailed procedures are required to guide nurses to manage patients’ ICANS, so as to improve the safety of patients and the promotion of CAR T-cell therapy

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Yang et al. (2025) studied this question.

synapsesocial.com/papers/69a75b00c6e9836116a218cahttps://doi.org/10.2478/fon-2025-0046
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P08.11.A MANAGEMENT OF IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME FOLLOWING CAR-T CELL THERAPY IN CLINICAL PRACTICE: A MULTICENTRIC, RETROSPECTIVE, REAL-WORLD ANALYSIS OF TREATMENT APPROACHES AND OUTCOMES2025
  2. 2Immune effector cell-associated neurotoxicity syndrome: integrative mechanisms, predictive biomarkers, and translational pathways for prevention in CAR T-cell therapy2026 · 2 citations
  3. 3Novel Treatment Modality for Chimeric Antigen Receptor T-cell Therapy Complications: A Case Report2024
  4. 4Beyond the Typical ICANS: Characterizing Non-ICANS Neurological Complications in CAR-T Therapy – A Retrospective Analysis2026
  5. 5Risk stratification for immune effector cell-associated neurotoxicity syndrome in patients receiving chimeric antigen receptor T cell therapy.2024 · 2 citations